'Black fungus' treatment runs short in India as new cases of infection emerge

Microscopic image of a mucormycosis fungal infection
(Image credit: Shutterstock)

New cases of mucormycosis, a potentially fatal fungal infection, continue to crop up among COVID-19 patients in India, but many regions are facing shortages of the drug used to treat the disease.

Mucormycosis, also called "black fungus," typically strikes people with weakened immune systems, such as those with diabetes and those taking immunosuppressive drugs — including the steroids sometimes used to treat COVID-19, Live Science previously reported. Experts suspect that the rise in cases may be to these steroids, administered both in hospitals and sometimes at home, as hospitals have recently been overrun. In addition, those receiving medicine or oxygen therapy at home may be more likely to pick up the mold from their surroundings, compared with those treated in a sterile, clinical setting.

Nicoletta Lanese
Channel Editor, Health

Nicoletta Lanese is the health channel editor at Live Science and was previously a news editor and staff writer at the site. She is a recipient of the 2026 AHCJ International Health Study Fellowship, with a project focused on antibiotic stewardship practices in Japan and the U.S. They hold a graduate certificate in science communication from UC Santa Cruz and degrees in neuroscience and dance from the University of Florida. Beyond Live Science, Lanese's work has appeared in The Scientist, Science News, the Mercury News, Mongabay and Stanford Medicine Magazine, among other outlets. Based in NYC, she also remains involved in dance and performs in local choreographers' work.